Why is the Imugene share price on ice today?

The Imugene share price isn't going anywhere on Monday.

| More on:
A businessperson sits at his desk in a cold office with snow and ice all around him and a frozen beard.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • The Imugene share price is frozen at 22.5 cents this morning 
  • It's been put on ice as the company gets ready to reveal a planned capital raise
  • According to the company, the raise will facilitate investment from two new institutional investors

The Imugene Limited (ASX: IMU) share price isn't going anywhere right now. The stock has been put into a trading halt earlier this morning pending the announcement of a capital raising.

The Imugene share price last traded at 22.5 cents.

Let's take a closer look at what's going on with the S&P/ASX 200 Index (ASX: XJO) biopharmaceutical favourite on Monday.

Why is the Imugene share price frozen on Monday?

The Imugene share price has been put in the freezer this morning as the company prepares to reveal a planned capital raising.

According to the company's request for a trading halt, the raise will "facilitate investment from two new institutional investors".

The stock will remain frozen until the company reveals more details or the market opens on Wednesday, whichever occurs first.

Imugene is an immuno-oncology-focused company developing therapies with the aim to treat cancerous tumours.

Its share price jumped nearly 7% last week on news it had dosed the first patient in its HER-Vaxx phase two trial.

The company reported a $37.9 million loss for financial year 2022, ending the period with around $99.9 million of cash.

Its coffers were bolstered by a $95 million capital raise in July 2021 when it offered new shares in the company for 30 cents apiece.

The Imugene share price has been underperforming lately. It has fallen 48% since the start of 2022. It's also currently 45% lower than it was this time last year.

For context, the ASX 200 has dumped 8% so far this year and 6% over the last 12 months.

Motley Fool contributor Brooke Cooper has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

CSL share price leaping higher amid $1.9 billion funding news

ASX 200 investors are bidding up the CSL share price on Wednesday.

Read more »

Two happy scientists analysing test results.
Healthcare Shares

Mesoblast share price rockets 36% on breaking FDA news

ASX investors are sending the Mesoblast share price soaring following promising FDA news.

Read more »

a doctor in white coat and stethoscope stands in front of a building holding an electronic device in his hands.
Healthcare Shares

Guess which ASX 200 healthcare share is jumping 7% on a guidance update

This healthcare share is performing better than expected in FY 2024.

Read more »

a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.
Earnings Results

Chemist Warehouse merger target Sigma reports 149% FY24 profit jump

This could be the last set of results from Sigma as we know it if its merger is approved.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

1 ASX healthcare stock that looks severely undervalued

I think this stock looks too cheap to miss.

Read more »

Stethoscope with a piggy bank and hundred dollar notes.
Healthcare Shares

Own Medibank shares? Here's why it's a rewarding day for you

Shareholders are getting a healthy boost today.

Read more »

Health professional looking at a laptop.
Healthcare Shares

Are CSL shares a must-buy in March?

Let's see what analysts are saying about this high-quality company.

Read more »

A woman jumps for joy with a rocket drawn on the wall behind her.
Healthcare Shares

This ASX healthcare stock is up 72% on FDA news and 'historic moment'

Huge gains are been recorded by this stock on Tuesday. But why?

Read more »